Incyte
Why Robinhood?
Robinhood gives you the tools you need to put your money in motion. You can buy or sell Incyte and other ETFs, options, and stocks.About INCY
Incyte Corp. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of proprietary therapeutics. It focuses on hematology and oncology, and inflammation and autoimmunity therapeutic areas.
INCY Key Statistics
Stock Snapshot
With a market cap of 20.1B, Incyte(INCY) trades at $100.64. The stock has a price-to-earnings ratio of 14.48.
On 2026-06-08, Incyte(INCY) stock moved within a range of $98.78 to $104.63. With shares now at $100.64, the stock is trading +1.9% above its intraday low and -3.8% below the session's peak.
Trading volume for Incyte(INCY) stock has reached 2.77M, versus its average volume of 1.75M.
Over the past 52 weeks, Incyte(INCY) stock has traded between a high of $112.29 and a low of $66.74.
Over the past 52 weeks, Incyte(INCY) stock has traded between a high of $112.29 and a low of $66.74.
INCY News
Oppenheimer analyst Jay Olson raised the firm’s price target on Incyte (INCY) to $107 from $90 and keeps a Perform rating on the shares after the company announ...
After Incyte (INCY) announced it has entered into an agreement to acquire Vega Therapeutics, a wholly owned subsidiary of Star Therapeutics, for $1.25B, Jefferi...
Incyte has agreed to buy Vega Therapeutics for up to $2 billion. Company-supplied Image Incyte INCY 1.13 %increase; green up pointing triangle has agreed to bu...
Analyst ratings
57%
of 30 ratingsMore INCY News
Incyte ( (INCY) ) has shared an announcement. On June 8, 2026, Incyte announced a definitive agreement to acquire Vega Therapeutics, a wholly owned subsidiary...
Mirum Pharmaceuticals (MIRM) and Incyte (INCY) announced that Phase 2 results from the PROGRESS study evaluating zilurgisertib, an investigational ALK2 inhibito...
Incyte (INCY) announced an update on their ongoing clinical study. Unlock trusted, data-backed investing tools with TipRanks Premium, from analyst ratings and...
In late May 2026, Incyte reported that its pivotal Phase 3 frontMIND trial showed tafasitamab (Monjuvi/Minjuvi) plus lenalidomide and R-CHOP significantly impro...
People also own
Similar Marketcap
This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.
Popular Stocks
This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset
Newly Listed
This list is generated by showing companies that recently went public.